Skip to main content

Table 1 The possible suppressors for SARS-CoV-2 infection

From: Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19

Drug/methods Pathway Previously used in References
Camostat mesylate TMPRSS2 suppressor, the effect on S proteins Treatment of chronic pancreatitis, postoperative reflux esophagitis, and SARS-CoV [5, 92]
Olumiant (Baricitinib) JAK suppressor, the effect on S proteins Treatment of rheumatoid arthritis [93]
rhACE2 (APN01) Decrease in proteolytic binding peptide angiotensin II SARS-CoV infections, cardiovascular disease [5, 94]
Umifenovir (Arbidol/ARB) Preventing HA protein-interceded membrane fusion influenza infection [95]
T-705 (Favipiravir) Inhibiting RdRp influenza viruses, WNV, yellow fever virus, FMDV [96, 97]
Abacavir (Ziagen) RTIs (reverse-transcriptase inhibitors) Treatment of HIV [98]
Roflumilast (Daxas/Daliresp) Preventing PDE4 COPD [98]
Almitrine mesylate is a respiratory stimulant COPD [98]
Chloroquine phosphate IFN-α pathway antimalarial [99, 100]
Remdesivir RdRp inhibitor Treatment of Ebola and Marburg infections [101]
Convalescent plasma viral-specific antibodies Ebola virus, H1N1, SARS-CoV-1, MERS-CoV [102]